Detalles de la búsqueda
1.
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Respir Res;
24(1): 135, 2023 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37210543
2.
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
Respir Res;
23(1): 36, 2022 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35183167
3.
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.
J Asthma Allergy;
17: 273-290, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38562251
4.
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis.
Front Allergy;
3: 881218, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35769575
5.
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study.
J Asthma Allergy;
15: 1593-1604, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36387835
6.
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis.
Front Med (Lausanne);
9: 950883, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36117962
Resultados
1 -
6
de 6
1
Próxima >
>>